Results 81 to 90 of about 770 (178)

Biomarkers to inform the management of polycystic ovary syndrome: A review of systematic reviews

open access: yesClinical Endocrinology, Volume 101, Issue 5, Page 535-548, November 2024.
Abstract Introduction Polycystic ovarian syndrome (PCOS) is the commonest endocrine condition affecting reproductive age women. Many biomarkers may aid assessment and management, however evidence is limited on their utility in clinical practice.
Hugo Walford   +5 more
wiley   +1 more source

Correlation of NAFLD with betatrophin.

open access: yes, 2017
Correlation of NAFLD with betatrophin.
Xiaojuan Shao (3709594)   +9 more
core   +1 more source

Advances in the Use of Biologics and Biomaterials toward the Improvement of Pancreatic Islet Graft Survival in Type 1 Diabetes

open access: yesAdvanced NanoBiomed Research, Volume 4, Issue 3, March 2024.
Although islet transplantation has the potential to serve as a curative treatment for type 1 diabetes, there are many hurdles to achieving long‐term islet graft survival. This review discusses the recent advances in strategies to improve islet survival function using exogenous compounds and conformal coatings as a promising tool for improving islet ...
Michael Yilma Yitayew   +2 more
wiley   +1 more source

Serum Betatrophin Concentrations and the Risk of Incident Diabetes: A Nested Case-Control Study from Chungju Metabolic Disease Cohort [PDF]

open access: yesDiabetes & Metabolism Journal, 2017
BackgroundBetatrophin is a newly identified hormone derived from the liver and adipose tissue, which has been suggested to regulate glucose and lipid metabolism.
Seung-Hwan Lee   +4 more
doaj   +1 more source

Weight loss partially restores glucose-driven betatrophin response in humans

open access: yes, 2016
Context: Recently a potential role of betatrophin was shown in the postprandial switch from lipid to glucose metabolism. Objective: To analyse whether obesity is associated with altered postprandial betatrophin response and whether this could be restored
Bobbert, T.   +10 more
core   +1 more source

Serum betatrophin, TG and ALT in subjects according to LFC.

open access: yes, 2017
(A) TG, triglyceride; (B) Betatrophin; (C) ALT, alanine transaminase. (A) TG and (C) ALT were significantly higher in patients with LLFC and HLFC than in controls.
Xiaojuan Shao (3709594)   +9 more
core   +1 more source

Table1_Analysis of the Expression and Prognostic Potential of a Novel Metabolic Regulator ANGPTL8/Betatrophin in Human Cancers.docx

open access: yes, 2021
The angiopoietin-like protein (ANGPTL) family members, except for the novel atypical member ANGPTL8/betatrophin, have been reported to participate in angiogenesis, inflammation and cancer.
Kai Sun (140584)   +4 more
core   +1 more source

Image6_Analysis of the Expression and Prognostic Potential of a Novel Metabolic Regulator ANGPTL8/Betatrophin in Human Cancers.JPEG

open access: yes, 2021
The angiopoietin-like protein (ANGPTL) family members, except for the novel atypical member ANGPTL8/betatrophin, have been reported to participate in angiogenesis, inflammation and cancer.
Kai Sun (140584)   +4 more
core   +1 more source

Serum betatrophin level of newly diagnosed and chronic diabetic patients and its relationship with metabolic parameters: Betatrophin levels in diabetes

open access: yesChronic Diseases Journal, 2023
BACKGROUND: Angiopoietin-like protein 8 (ANGPTL8) that was originally called betatrophin is a novel growth factor which is mainly secreted by the liver and associated with diabetes. Hence, it can be considered as a clinical parameter for diagnosis or treatment of diabetes.
Vakili, Nadia   +6 more
openaire   +1 more source

Image4_Analysis of the Expression and Prognostic Potential of a Novel Metabolic Regulator ANGPTL8/Betatrophin in Human Cancers.TIF

open access: yes, 2021
The angiopoietin-like protein (ANGPTL) family members, except for the novel atypical member ANGPTL8/betatrophin, have been reported to participate in angiogenesis, inflammation and cancer.
Kai Sun (140584)   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy